Matrix metalloproteinase polymorphisms and bladder cancer risk

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11644-11648

  Kader, A Karim ^a   Shao, Lina ^a   Dinney, Colin P ^a   Schabath, Matthew B ^a   Wang, Yunfei ^a   Liu, Jun ^a   Gu, Jian ^a   Grossman, H Barton ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RISK; CONTROLLED STUDY; ENZYME POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CASE-CONTROL STUDIES; DNA; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; REFERENCE VALUES; RISK FACTORS; SMOKING; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 33846263433     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1212     Document Type: Article

References (21)

1. Dinney CPN, McConkey DJ, Millikan RE, et al. Focus on bladder cancer. Cancer Cell 2004;6:111-6.
2. Zeegers MPA, Tan FES, Dorant E, et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk. Cancer 2000;89:630-9.
3. Wu X, Zhao H, Suk R, et al. Genetic susceptibility to tobacco-related cancer. Oncogene 2004;23:6500-23.
4. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-21.
5. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
6. Gerhards S, Jung K, Koenig F, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 2001;57:675-9.
7. Gohji K, Fujimoto N, Komiyama T, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-87.
8. Zinzindohoue F, Lecomte T, Ferraz J-M, et al. Prognostic significance of mmp-1 and mmp-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11:594-9.
9. Grieu F, Li WQ, Iacopetta B. Genetic polymorphisms in the mmp-2 and mmp-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004;88:197-204.
10. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79.
11. Hu Z, Huo X, Lu D, et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin Cancer Res 2005;11:5433-9.
12. Fiotti N, Zivadinov R, Altamura N, et al. Mmp-9 micro satellite polymorphism and multiple sclerosis. J Neuroimmunol 2004;152:147-53.
13. Fornoni A, Wang Y, Lenz O, et al. Association of a decreased number of d(ca) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J Am Soc Nephrol 2002;13:2068-76.
14. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636-45.
15. Ozdemir E, Kakehi Y, Okuno H, et al. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 1999;161:1359-63.
16. Elkin M, Ariel I, Miao H-Q, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999;59:4111-8.
17. St-Pierre Y, Van Themsche C, Esteve PO, Emerging features in the regulation of mmp-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets Inflamm Allergy 2003;2:206-15.
18. Peters DG, Kassam A, St. Jean PL, et al. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999;30:2612-6.
19. Jormsjo S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000;86:998-1003.
20. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
21. Gakiopoulou H, Nakopoulou L, Siatelis A, et al. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003;9:5573-81.